Peanut Allergy
Odds for successful peanut oral immunotherapy fall with consecutive missed doses
SAN DIEGO — Odds for desensitization and remission fell as patients missed consecutive doses of peanut oral immunotherapy, according to a poster presented here.
Peanut allergy vaccine deemed safe, tolerable in phase 1 study
SAN DIEGO — A hypoallergenic therapeutic vaccine candidate for peanut allergy was safe and tolerable, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.
Response to peanut patch treatment increases through 60 months
SAN DIEGO — Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months, according to an abstract presented here.
Patients introduce allergens into their diets after using omalizumab
SAN DIEGO — Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.
Risks for food allergy increase with mixed diets in first 3 days of infancy
SAN DIEGO — Infants who did not exclusively feed on colostrum during their first 3 days of life were more likely to develop egg or peanut allergy, according to an abstract presented here.
Peanut oral immunotherapy desensitizes children with higher allergy thresholds
Following receipt of increasing peanut oral immunotherapy, or home-measured peanut butter, desensitization to peanut protein in children initially able to ingest more than half a peanut was achieved, according to study results.
Top in allergy/asthma: Dupilumab ineffective for peanut desensitization; asthma blood test
Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind placebo-controlled food challenge with at least 444 mg of peanut protein after receiving dupilumab for 24 weeks.
Top in allergy/asthma: ‘Psychosocial burden’ of food allergy; peanut allergy patch
Regardless of sociodemographic or clinical characteristics, children with food allergy face a significant psychosocial burden, according to a survey of caregivers published in The Journal of Allergy and Clinical Immunology: In Practice.
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.
Patch effective through 36 months in treating toddlers with peanut allergy
Two-thirds of toddlers with peanut allergy who used the VIASKIN Peanut patch from DBV Technologies completed an oral food challenge at 36 months without meeting criteria for stopping, according to a webinar held by the company.